GAITHERSBURG, Md., Sept. 4,
2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd.
(Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global
biopharmaceutical company dedicated to discovering, developing,
manufacturing, and delivering new generations of vaccines and
therapeutic biologics for infectious diseases and cancer, today
announced that the board of directors of the Company (the "Board")
has appointed Mr. Xu Wang as the
Chief Executive Officer of the Company. He succeeds Mr.
Dave Chenn and Dr. Hui Shao, who step down from the Company's
Interim Chief Executive Officer and Co-Chief Executive Officer
position, respectively. Mr. Xu Wang
has served as the Company's Chief Operation Officer since
June 2024, and he will no longer
assume such role upon becoming the Chief Executive Officer of the
Company.
The Board has also approved the appointment of Dr. Hui Shao as the Chief Business Officer of the
Company, responsible for global strategic planning and global
transactions, and the transition of Ms. Rachel Yu from the role of Interim Chief
Financial Officer to Chief Financial Officer of the Company. Ms. Yu
is also a partner at Oceanpine Capital's healthcare practice since
December 2021, where she is
responsible for formulating the overall investment strategies in
the healthcare sector and taking principal leadership
responsibility in post-investment management of portfolio
companies.
In addition to these leadership transitions, the Company also
announced the appointment of Dr. Hui
Shao as the Vice Chairman of the Board, and the appointment
of Mr. Xu Wang as a new member of
the Board. The leadership transitions and board appointments
became effective on September 1,
2024.
About LakeShore Biopharma
LakeShore Biopharma, previously known as YS Biopharma, is a
global biopharmaceutical company dedicated to discovering,
developing, manufacturing, and delivering new generations of
vaccines and therapeutic biologics for infectious diseases and
cancer. It has developed a proprietary PIKA® immunomodulating
technology platform and a new generation of preventive and
therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B,
Influenza, Shingles, and other virus infections. The Company
operates in China, the United States, Singapore, and the
Philippines, and is led by a management team that combines
rich local expertise and global experience in the biopharmaceutical
industry. For more information, please visit
investor.lakeshorebio.com.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: LakeShoreBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lakeshore-biopharma-announces-leadership-transitions-302237903.html
SOURCE LakeShore Biopharma Co., Ltd.